With patients in almost every country on earth receiving affordable generic drugs produced in India, the south Asian nation can claim with some degree of force to be ‘the pharmacy to the world.’ Not only are Indian medicines consumed in the US and EU, but enterprising Indian companies are increasingly looking towards huge underserved developing markets across the globe.
Furthermore, Indian companies are tentatively scaling the value chain in their product offerings and moving into the R&D-intensive but potentially lucrative field of biologics; a handful of Indian biosimilars having already been approved in highly-regulated international markets. Multinationals are still being drawn to India too, helped by incentivising policies such as Prime Minister Modi’s ‘Make in India’ initiative, as well as the enduring draw of the huge population and unmet medical need within the Indian domestic market.
Designed for pharmaceutical executives seeking insights on the Indian market, this report also explores the challenges presented by a rise in lifestyle-related non-communicable diseases such as heart disease, strokes and diabetes. It also explores the pricing pressures pharmaceutical companies are facing resulting from a new National Health Policy.
The government officials, regulators, MNC affiliate heads and domestic champions whose comments form the backbone of this report tackle these key issues along with a host of others, including corporate social responsibility, human resources, e-health, the nation’s hubs of development and innovation, and how Indian companies have stepped up their quality compliance game following a spate of US FDA warning letters.
Other key topics covered in this report include the startling growth of the contract research and contract manufacturing sectors as pharma companies divest an ever-increasing number of non-core activities; the enduring importance of the domestic market, of which Indian companies hold a 77 percent market share; and how Indian organizations are consolidating their presence abroad through a series of acquisitions and tie-ups with international entities.